Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>BioNTech SE’s second quarter of 2026 results reflect a company in transition, moving from its origins as a pioneering mRNA vaccine developer toward a diversified multiproduct biopharmaceutical organization, with a strong focus on oncology.</li>
<li>Leadership changes were announced with Guido Oelkers set to assume the CEO role by early 2027, bringing experience in strategic scaling and global commercialization, signaling the company’s intent to accelerate expansion and operational efficiency.</li>
<li>Operationally, BioNTech reported revenues of €106 million for Q2 2026, a decline from €261 million the prior year, largely due to reduced demand for its COVID-19 vaccine, particularly in the U.S., and reduced milestone payments.</li>
</ul>


BioNTech SE’s second quarter of 2026 results reflect a company in transition, moving from its origins as a pioneering mRNA vaccine developer toward a diversified multiproduct biopharmaceutical organization, with a strong focus on oncology.
Leadership changes were announced with Guido Oelkers set to assume the CEO role by early 2027, bringing experience in strategic scaling and global commercialization, signaling the company’s intent to accelerate expansion and operational efficiency.
Operationally, BioNTech reported revenues of €106 million for Q2 2026, a decline from €261 million the prior year, largely due to reduced demand for its COVID-19 vaccine, particularly in the U.S., and reduced milestone payments.


BioNTech Is Moving Beyond COVID — Three Oncology Programs Could Define What Comes Next!